Authors
Latest:
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research RecommendationsThis review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Latest:
Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLCA proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
Latest:
Addition of Tremelimumab to Durvalumab Regimen Induces Greater Survival Outcomes in PD-L1–Negative NSCLCThe phase 3 POSEIDON trial showed superior overall survival in patients with PD-L1–negative metastatic non–small cell lung cancer who were given durvalumab and chemotherapy plus tremelimumab.
Latest:
Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCCCancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.
Latest:
Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung CancerOriginal research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.
Latest:
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer OrganizationsAlthough female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Lindsey Roeker, MD, Discusses Potential for BTK Inhibition Plus Umbralisib/Ublituximab in CLLLindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.
Latest:
Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMOCancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Adjuvant Pembrolizumab Shows Statistical Improvement in Survival in ccRCCAdjuvant pembrolizumab resulted in a reduction in the risk of death in patients with ccRCC.
Latest:
Emerging Strategies to Manage Relapsed and/or Refractory Multiple MyelomaJames J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
Disorders of Sex Development and Malignant Germ Cell TumorsKey points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.
Latest:
HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in CareClosing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.
Latest:
Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial CancersCara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Latest:
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple MyelomaInvestigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Latest:
Key Takeaways on the Management of Clear-Cell RCCIn closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
